Every 10-Q that Bruker Corporation (BRKR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRKR filings page.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up from $797.4 million, with growth across BSI CALID, BSI NANO, and BEST. Gross profit rose to $416.0 million, but a $134.9 million goodwill impairment and other charges drove a consolidated operating loss of $65.3 million. After interest and other income of $24.6 million, taxes, and $10.9 million of preferred dividends, net loss attributable to common shareholders was $62.9 million, or $(0.41) per share, versus $0.05 earnings a year earlier.
For the first half of 2026, revenue was $1,661.9 million and net loss to common shareholders was $59.4 million. Bruker deployed $81.1 million of consideration (net of cash acquired) on acquisitions, including the remaining 60% of Tofwerk, adding goodwill of $35.4 million and identifiable intangibles (technology $42.7 million, customer relationships $3.5 million, tradename $1.6 million). Total goodwill decreased to $1,429.8 million after impairments of $98.4 million for the CST reporting unit and $36.5 million for the BSB reporting unit. Operating cash flow was a $6.2 million use, compared with $62.5 million use a year earlier; cash, cash equivalents and restricted cash were $189.1 million, and long-term debt was $1,814.7 million. Remaining performance obligations reached $2,775.6 million, and a post‑June 30 reorganization into BIOS, BMID, BSI NANO, and BEST will trigger an interim goodwill impairment analysis in the third quarter of 2026.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.
Bruker Corporation reported Q3 2025 results showing total revenue of $860.5 million, slightly below last year’s $864.4 million. A $96.5 million goodwill impairment and higher cost of product revenue drove an operating loss of $51.8 million versus income of $68.1 million a year ago. Net loss attributable to common shareholders was $62.4 million (basic and diluted $(0.41) per share).
Year‑to‑date, operating cash flow was $(95.7) million. The company strengthened liquidity with net proceeds of $669.5 million from issuing 6.375% Series A Mandatory Convertible Preferred Stock. Cash and cash equivalents rose to $293.1 million as of September 30, 2025, while long‑term debt was $1.98 billion. Bruker completed acquisitions including Recipe Chemicals + Instruments, with 2025 acquired businesses contributing $11.5 million of revenue and $2.2 million of pre‑tax losses. Total shareholders’ equity increased to $2.45 billion. Common shares outstanding were 151,941,144 as of October 30, 2025.